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OBJECTIVE — Althoughmetabolicsyndromeisrelatedtoanincreasedriskofcoronaryheart
disease (CHD) events, individuals with metabolic syndrome encompass a wide range of CHD
risk levels. This study describes the distribution of 10-year CHD risk among U.S. adults with
metabolic syndrome.
RESEARCH DESIGN AND METHODS — Metabolic syndrome was deﬁned by the
modiﬁed National Cholesterol Education Program (NCEP)/Third Adult Treatment Panel (ATP
III) deﬁnition among 4,293 U.S. adults aged 20–79 years in the National Health and Nutrition
Examination Survey 2003–2004. Low-, moderate-, moderately high–, and high-risk statuses
were deﬁned as 6, 6 to 10, 10–20, and 20% probability of CHD in 10 years (based on
NCEP/ATP III Framingham risk score algorithms), respectively; those with diabetes or preex-
isting cardiovascular disease were assigned to high-risk status.
RESULTS — The weighted prevalence of metabolic syndrome by NCEP criteria in our study
was 29.0% overall (30.0% in men and 27.9% in women, P  0.28): 38.5% (30.7% men and
46.9%women)wereclassiﬁedaslowrisk,8.5%(7.9%menand9.1%women)wereclassiﬁedas
moderate risk, 15.8% (23.4% men and 7.6% women) were classiﬁed as moderately high risk,
and 37.3% (38.0% men and 36.5% women) were classiﬁed as high risk. The proportion at high
risk increased with age but was similar among Hispanics, non-Hispanic whites, and non-
Hispanic blacks.
CONCLUSIONS — Althoughmanysubjectswithmetabolicsyndromehavealowcalculated
risk for CHD, about half have a moderately high or high risk, reinforcing the need for global risk
assessmentinindividualswithmetabolicsyndrometoappropriatelytargetintensityoftreatment
for underlying CHD risk factors.
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T
he metabolic syndrome is a cluster
ofriskfactorsoftenlinkedtoinsulin
resistance that has been shown to
increase the risk for development of car-
diovascular disease (CVD). Individuals
with metabolic syndrome have an in-
creased risk of coronary heart disease
(CHD) and CVD mortality (1,2). Global
risk assessment using Framingham risk
prediction algorithms is often the initial
evaluation of CHD risk in subjects with
multipleriskfactors,includingthosewith
metabolic syndrome (3). Although it is of-
ten assumed that individuals with meta-
bolic syndrome have a high risk of CVD,
many have only borderline elevations in
risk factors and thus may actually have ei-
ther a low or intermediate risk of CVD (4).
Therefore,assessmentofglobalriskofCHD
in individuals with metabolic syndrome
may be helpful to most appropriately target
the intensity of cardiometabolic risk factor
interventions for prevention of diabetes
or cardiovascular disease.
Theaimofthisarticlewastocalculate
theglobalriskofCHDinadultswithmet-
abolic syndrome in the U.S. to better
characterize the diversity in their risk of
CHD using the data from the National
HealthandNutritionExaminationSurvey
(NHANES) 2003–2004. In addition, we
will examine the global risk of CHD in
individuals with metabolic syndrome
across sex, ethnicity, and age-groups and
examine goal attainment and distance to
recommended levels for key CHD risk
factors.
RESEARCH DESIGN AND
METHODS— Among 4,293 adults
aged 20–79 years in the NHANES 2003–
2004,3,034hadcompleteriskfactordata
allowing calculation of 10-year risk of a
“hard ” CHD event (nonfatal myocardial
infarction or CHD death) according to
National Cholesterol Education Program
(NCEP)/Third Adult Treatment Panel
(ATP III) Framingham risk score criteria
(5). We deﬁned metabolic syndrome by
themodiﬁedNCEPdeﬁnitionif3ofthe
following were present: 1) waist circum-
ference 102 cm for men or 88 cm for
women, 2) triglyceride level 1.69
mmol/l (150 mg/dl) if fasting, 3) HDL
cholesterol level 1.04 mmol/l (40 mg/
dl) if male or 1.29 mmol/l (50 mg/dl) if
female, 4) blood pressure 130/85
mmHg or receiving antihypertensive
treatment, and 5) fasting glucose level
5.6 mmol/l (100 mg/dl) or receiving
drug treatment for elevated glucose. Par-
ticipants were classiﬁed as not having
metabolic syndrome after conﬁrming the
absence of at least three metabolic syn-
drome risk factors. We also conducted
similar analyses among individuals iden-
tiﬁed with metabolic syndrome by the In-
ternational Diabetes Federation criteria
requiring increased waist circumference
as deﬁned above plus 2 of the other cri-
teria (based on the same cut points as
shownabove,exceptforalowerwaistcir-
cumference cut point for Hispanics of
80 cm for women and 90 cm for men
as recommended by the International Di-
abetes Federation for individuals of Cen-
tral or South American ancestry) (6).
Diabetes was deﬁned as having a fasting
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aftera12-hfast,anonfastingglucoselevel
of 11.1 mmol/l (200 mg/dl), use of oral
hypoglycemic agents or insulin, or self-
reported diagnosis of diabetes. We exam-
ined the proportion of individuals with
and without metabolic syndrome among
each risk group that had a low (6%),
moderate (6 to 10%), moderately high
(10–20%), or high (20%) 10-year
probability for CHD on the basis of the
Framingham risk algorithm (5) and clas-
siﬁed according to the American Heart
Association (AHA)/National Heart, Lung,
and Blood Institute (NHLBI) scientiﬁc
statement on metabolic syndrome (3),
which deﬁnes moderately high risk as a
10–20%andhighriskasa20%10-year
probability of CHD. Whereas this state-
mentalsodeﬁnedmoderateriskas10%
with 2 risk factors present, “intermedi-
ate” risk has been suggested previously to
be a CHD risk of 0.6–2.0% per year (7),
so we have therefore deﬁned moderate
risk as 6 to 10% and low risk as 6% risk
in10yearsforthepurposesofthisarticle.
Individuals with preexisting diabetes (as
deﬁned above) or self-reported CVD (in-
cluding heart attack, heart failure, or
stroke) were assigned to the high-risk
group. We stratiﬁed our analyses by age-
group, sex, and ethnicity.
We also examined the percentage of
subjects with metabolic syndrome with
measurementsthatwerenotattherecom-
mended levels for HDL cholesterol, tri-
glycerides, systolic blood pressure,
diastolic blood pressure, fasting glucose,
and LDL cholesterol. Mean distances
from recommended levels for each of
these risk factors were calculated among
all those not at goal. Distance from goal
was calculated as the difference between
the actual levels and recommended goal.
Goals for blood pressure were 140/90
mmHg or 130/80 mmHg if diabetes or
chronic kidney disease was present. The
LDL cholesterol goal for those with a low
risk was 160 mg/dl, for those with a
moderate to moderately high risk (6–
20%) it was 130 mg/dl, and for those
with a high risk (20%, diabetes, or
CVD) it was 100 mg/dl. Goals for fast-
ing glucose were 100 mg/dl, for HDL
cholesterol were 40 mg/dl (men) and
50 mg/dl (women), and for triglycer-
ides were 150 mg/dl, on the basis of
revised AHA/NHLBI metabolic syndrome
recommendations (5).
LDL cholesterol was calculated using
the Friedewald equation (LDL choles-
terol  total cholesterol  HDL choles-
terol  1⁄5 triglycerides) if triglycerides
were 400 mg/dl. HDL cholesterol levels
were measured by a precipitation method
using a heparin-manganese chloride mix-
ture on a Hitachi 704 analyzer (Boehr-
inger Mannheim Diagnostics, India-
napolis,IN).Totalcholesterolandtriglyc-
erides were measured enzymatically after
hydrolyzation to glycerol on a Hitachi
704analyzer.Glycohemoglobinwasmea-
sured using a glycohemoglobin analyzer.
Blood pressure was measured using a
mercury sphygmomanometer and taking
the average of four readings. Detailed
specimen and data collection are dis-
cussed in the NHANES Laboratory/
Medical Technologists Procedures Manual
(8).
Cross-tabulation procedures with
SUDAAN software were used for popula-
tion-weighted percentages. The 
2 test of
proportions and ANOVA tests for com-
paring means were used to compare the
extent of positive risk factors for each pa-
rameter by sex and ethnicity. SAS statisti-
cal software (version 9.1.3; SAS Institute,
Cary, NC) as well as SUDAAN statistical
software (version 9.0.1; Research Trian-
gle Institute, Research Triangle Park, NC)
wereusedforanalysisandcomputationof
weighted estimates for projection to the
U.S. population in 2003–2004.
RESULTS
10-year global risk of individuals
with metabolic syndrome
The 2003–2004 NHANES weighted
prevalence of metabolic syndrome as de-
ﬁned by the AHA/NHLBI modiﬁed
NCEP/ATP III deﬁnition was 29.0% (the
unweightedprevalencewas32.0%,based
on 971 of 3,034 subjects being classiﬁed
with metabolic syndrome). Among those
with metabolic syndrome, 38.5% had a
calculated 10-year risk for CHD of 6%
(low), 8.5% had a 10-year CHD risk of 6
to 10% (moderate), 15.8% had a 10-
year CHD risk of 10–20% (moderately
high), and 3.5% had a 10-year CHD risk
of 20% (high). The remaining 33.7% of
subjectswithmetabolicsyndromehaddi-
abetes and/or CVD, which would put
them in the highest risk category. This
contrasts with those without metabolic
syndrome, of whom a signiﬁcantly higher
proportion had a low risk (79.7%) and
lower proportions had a moderate
(6.3%), moderately high (8.2%), or high
risk (0.9%) or had diabetes and/or CVD
(4.9%) (P  0.001) (Fig. 1). Logistic re-
gression shows that the odds of being cat-
egorized as having a high risk in those
subjects with metabolic syndrome is 9.68
(95% CI 7.53–12.45), unadjusted, and
after age adjustment, although this risk is
attenuated, it remains highly signiﬁcant:
odds 6.05 (4.61–7.93).
Althoughasimilarproportionofmale
versus female subjects with metabolic
syndrome were categorized as having a
high CHD risk (20% 10-year risk of
CHD, diabetes, and/or CVD) (38.0 vs.
36.5%), 23.4% of men but only 7.6% of
women were classiﬁed as having a mod-
eratelyhighrisk(P0.001betweenmen
and women across risk categories). There
were, however, no signiﬁcant differences
in CHD risk distribution when different
ethnic groups were compared (Fig. 2),
Figure 1—Proportion of individuals with and without metabolic syndrome (MetS) classiﬁed by
10-yearCHDriskgroup:low-(6%),moderate-(6to10%),moderatelyhigh–(10–20%),and
high- (20% or diabetes [DM]/CVD) risk groups. P  0.001 comparing distribution of risk
groups between those with versus without metabolic syndrome.
Global risk assessment and metabolic syndrome
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Hispanics, non-Hispanic whites, and
non-Hispanic blacks being 35.6, 36.3,
and 41.6%, respectively (P  0.27).
Among individuals with metabolic syn-
drome, from logistic regression analyses
both unadjusted and age adjusted, there
werenosigniﬁcantdifferencesinthelike-
lihood of high-risk status by sex or eth-
nicity (results not shown). Across age-
groups, the proportion of individuals
with metabolic syndrome at high risk
(20% 10-year risk or diabetes/CVD) in-
creased dramatically with age from 4.4%
in those aged 20–29 years to 75.8% in
those aged 70–79 years among men and
17.1% to 55.0%, respectively, among
women (P  0.001 when risk category
distributions by age for both men and
women were compared) (Fig. 3).
A very similar risk distribution was
calculated for subjects with metabolic
syndrome identiﬁed under the Interna-
tional Diabetes Federation criteria, for
whom an overall weighted prevalence of
26.8% (unweighted prevalence 29.0%)
for metabolic syndrome was obtained. Of
these subjects, 39.6% had a low risk,
8.5% had a moderate risk, 15.5% had a
moderately high risk, and 3.4% had a
highrisk,and33.2%haddiabetesorCVD
whentheInternationalFederationcriteria
for metabolic syndrome were used. By
sex, 37.1% of men and 35.9% of women,
and by ethnicity, 34.3% of Hispanics,
35.6% of non-Hispanic whites, and
40.7%ofnon-Hispanicblacks(P0.001
across sex) were deﬁned as having a high
risk, including CVD or diabetes, compa-
rable to the proportions obtained using
the NCEP deﬁnition above.
Prevalence of metabolic syndrome
risk factors
Among individuals with metabolic syn-
drome (classiﬁed by the NCEP ATP III
deﬁnition), the most common risk factor
components were increased waist cir-
cumference (93.4% of subjects with met-
abolic syndrome) followed by elevated
triglycerides(64.6%ofsubjectswithmet-
abolic syndrome). Elevated LDL choles-
terol, although among the least common
of the associated risk factors, was still
present in 40.2% of subjects with meta-
bolicsyndrome.Whensubjectswithmet-
abolic syndrome and with diabetes were
compared with those without diabetes,
those with diabetes showed a trend to-
ward a lower prevalence of abnormal
HDL (50.1% vs. 62.8% in those subjects
with metabolic syndrome without diabe-
tes) and triglycerides (59.3% vs. 65.9%).
Mean levels, proportion not at goal,
and distance from goal of selected
risk factors in subjects with
metabolic syndrome
Mean levels of CVD risk factors for sub-
jects with and without metabolic syn-
drome are shown in Table 1. Of all
individuals with metabolic syndrome,
34.4% had systolic blood pressure not at
recommended levels, whereas 17.9% had
diastolicbloodpressureabovetherecom-
mended levels. Of those not at goal for
blood pressure, mean blood pressures
were 151 mmHg for systolic and 91
mmHg for diastolic, with an average dis-
tance from goal of 16 mmHg for systolic
and 5 mmHg for diastolic blood pressure.
Of all individuals with metabolic syn-
drome, 40.2% had LDL cholesterol that
was not controlled to recommended lev-
Figure 3—Distribution of 10-year estimated risk for CHD by age-group stratiﬁed by sex: low
(6%), moderate (6 to 10%), moderately high (10–20%), and high (20% or diabetes or
CVD). P  0.001 comparing distribution of risk groups across age-groups for both men and
women.
Figure2—Distributionof10-yearestimatedriskforCHD:low-(6%),moderate-(6to10%),
moderately high– (10–20%), and high- (20% or diabetes or CVD) risk individuals with meta-
bolicsyndromestratiﬁedbysexandrace.P0.001comparingdistributionofriskgroupsbetween
men and women. NH, non-Hispanic.
Hoang and Associates
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mg/dl (averaging 37 mg/dl from goal) in
those not at goal. Overall, HDL choles-
terollevelsin53.4%ofmenand68.1%of
women with metabolic syndrome were
below recommended levels, and 56.3%
were not at goal for fasting glucose, with
these individuals averaging 23 mg/dl
from goal. As expected, subjects without
metabolic syndrome had signiﬁcantly
lower levels of all measures (signiﬁcantly
higher for HDL cholesterol), with signiﬁ-
cantly lower proportions not at goal or
recommended levels (Table 1).
CONCLUSIONS — Whereas indi-
viduals with metabolic syndrome have a
greaterriskofCHDeventscomparedwith
those without metabolic syndrome (1,2),
the heterogeneity in CHD risk among in-
dividuals with metabolic syndrome has
not been fully described. The present
study is unique in describing the overall
risk distribution of all individuals with
metabolic syndrome and shows that a
sizeable proportion of individuals with
metabolic syndrome actually have a low
global risk of CHD. However, more than
one-third of adults with metabolic syn-
dromeareinthehigh-riskgroup(thema-
jority classiﬁed as such because of
preexisting diabetes or CVD, and fewer
subjectswithmultipleriskfactorsprovid-
ing an estimated 10-year risk of CHD of
20%). Previous estimates of global risk
in persons with metabolic syndrome (4)
were based on an earlier NHANES survey
(1988–1994) and included individuals
aged 30–74 years without known diabe-
tes or CVD; therefore, the full-spectrum
of risk was not fully appreciated in that
report. Moreover, our study is unique in
showing the distance of metabolic syn-
drome and non-metabolic syndrome risk
factors from recommended or goal levels
and has shown that one-third of subjects
with metabolic syndrome are not at rec-
ommended blood pressure levels, 40%
are not at recommended LDL cholesterol
goals, and more than half have above-
normal levels of triglycerides and glucose
and below-normal levels of HDL choles-
terol. Such information may be of use to
clinicians in deciding how they should
approach risk assessment in individuals
with metabolic syndrome, as well as how
aggressively to treat it.
There are several limitations to our
study. First, although the NCEP/ATP III
risk algorithm used in this study incorpo-
rated many criteria found in the Framing-
ham coronary disease prediction
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and obesity, which could potentially af-
fect risk estimation in subjects with met-
abolic syndrome in the multiethnic U.S.
population,eventhoughthesefactorsdid
not add to prediction of CHD in the orig-
inal Framingham cohort of primarily
Caucasian subjects. Although the Fra-
mingham risk equation has been vali-
dated in some ethnic populations in
previous reports (9), it may or may not be
fully applicable for multiethnic popula-
tions such as those in the most recent
NHANES 2003–2004 survey. Our analy-
sis did not show estimated CHD risk to
differbyethnicityamongindividualswith
metabolic syndrome. Populations such as
Hispanics have lower CHD rates (10), so
it is also possible we may have overesti-
mated risk in our subset of Hispanics.
Conversely, despite blacks having poorer
CVDoutcomes,ouranalysisdidnotiden-
tifyestimatedCHDrisktobesigniﬁcantly
greater among blacks with metabolic syn-
drome. Certain factors that may relate to
poorer outcomes in blacks (e.g., left ven-
tricular hypertrophy), which are part of
neither the metabolic syndrome deﬁni-
tion nor the Framingham risk algorithms
used, may help explain this result. Sec-
ond, the NCEP/ATP III algorithm does
not take into account family history of
premature CHD or new markers (e.g., C-
reactive protein) or subclinical measures
of CHD, which may be more common in
subjects with metabolic syndrome,
thereby potentially underestimating risk
in certain individuals. For example, it has
beenshownthatwithinagivencalculated
risk strata (e.g., 10–20% CHD risk), ac-
tual CHD event risk varied severalfold ac-
cordingtolevelofcoronarycalciumscore
(11). In addition, as information on CVD
wasbasedonself-report,itispossiblethat
these numbers could be underestimated,
which would result in a lower overall risk
of CHD than may actually be the case.
Finally, this study only addresses 10-year
risk for CHD; lifetime CHD risk is sub-
stantially greater and may be a more rele-
vant end point for the purposes of
targeting therapy (12).
In summary, a wide spectrum of esti-
mated risk of CHD exists in U.S. adults
with metabolic syndrome; about one-
third of those with metabolic syndrome
have a high risk of CHD (either due to
preexisting CHD, diabetes, or 20% cal-
culated risk of CHD), and approximately
one-half have a 10% risk for CHD.
Theseproportionsaresigniﬁcantlyhigher
in individuals with versus without meta-
bolic syndrome. Speciﬁcally, more than
one-third of men with metabolic syn-
drome are of high-risk status. Finally,
many individuals with metabolic syn-
drome have measurements that remain a
signiﬁcant distance from recommended
or normal levels of lipids, blood pressure,
and/or glucose. These ﬁndings highlight
the importance of global risk assessment
in individuals with metabolic syndrome
to appropriately intensify treatment of
their cardiometabolic risk factors.
Acknowledgments— Partsofthisstudywere
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